Vyvgart (efgartigimod alfa-fcab) is a targeted therapy for myasthenia gravis known as an FcRn blocker. It works by reducing harmful antibodies in the body that interfere with nerve-to-muscle communication, which is what causes muscle weakness and fatigue in MG.
It is currently FDA-approved for adults with generalized MG Show Full Answer
Vyvgart (efgartigimod alfa-fcab) is a targeted therapy for myasthenia gravis known as an FcRn blocker. It works by reducing harmful antibodies in the body that interfere with nerve-to-muscle communication, which is what causes muscle weakness and fatigue in MG.
It is currently FDA-approved for adults with generalized MG who test positive for acetylcholine receptor (AChR) antibodies — which covers about 80% of people with MG. Exciting news on the horizon — a Phase 3 trial showed Vyvgart may also help people who test negative for the most common MG antibodies (called seronegative MG), including those who are "triple seronegative."
The manufacturer is aiming to submit an application to the FDA to expand approval to cover these groups by the end of 2025. If approved, Vyvgart could become the only FcRn blocker with such a broad treatment label, which would be a big deal for people who currently have very limited options.
Here's a quick summary of where things stand:
- ✅ Currently approved — Adults with generalized MG who are AChR- or MuSK-positive
- 🔬 In progress — Potential expansion to seronegative and triple seronegative MG subtypes
- 📅 Timeline — FDA application expected by end of 2025
If you're wondering whether Vyvgart might be right for your situation, it's worth having a conversation with your healthcare provider about your antibody status and treatment options.
May 13
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
